TWi Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Cutting-Edge Clinical Development

NEW YORK, N.Y. – February 11, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by TWi Biotechnology, Inc. A top biopharmaceutical company based in Taiwan, TWi Biotechnology selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.

“The Medidata platform has been broadly adopted globally and using it allows TWi to be more efficient, while ensuring investigative sites and clinical research coordinators are familiar and engaged with the technology,” said Dr. Calvin Chen, TWi Biotechnology’s president. “We’re pleased to be collaborating with Medidata as we work to address unmet medical needs and continue to provide innovative, high- quality treatments to patients worldwide.”

TWi Biotechnology is focused on developing innovative new therapies for unmet medical needs in the areas of metabolism, orphan diseases and dermatology. To optimize a Phase-II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®). In addition to enhancing productivity through real-time data entry, Medidata’s technology solutions are providing TWi Biotechnology with better clinical trial oversight that leads to earlier, more informed decision-making opportunities.